Tazobactam

Summary

Tazobactam (CHEMBL404) is an approved small-molecule antimicrobial agent (ATC J01CG02); indicated across 24 conditions including bacterial infectious disease and pseudomonas infection.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: J01CG02
• Indications: 24 conditions
• Clinical trials: 69
• Chemistry: 300.29 Da · C10H12N4O5S

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL404
Name	Tazobactam
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	123630
ChEBI	CHEBI:9421
ATC	J01CG02
Molecular formula	C10H12N4O5S
Molecular weight	300.29
InChIKey	LPQZKKCYTLCDGQ-WEDXCCLWSA-N

SMILES: C[C@@]1([C@@H](N2[C@H](S1(=O)=O)CC2=O)C(=O)O)CN3C=CN=N3

IUPAC name: (2S,3S,5R)-3-methyl-4,4,7-trioxo-3-(triazol-1-ylmethyl)-4lambda6-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid

ChEBI definition: A member of the class of penicillanic acids that is sulbactam in which one of the exocyclic methyl hydrogens is replaced by a 1,2,3-triazol-1-yl group; used (in the form of its sodium salt) in combination with ceftolozane sulfate for treatment of complicated intra-abdominal infections and complicated urinary tract infections.

Pharmacological roles (ChEBI): antimicrobial agent, antiinfective agent, EC 3.5.2.6 (β-lactamase) inhibitor.

Also known as: CL 298,741, CL-298741, NSC-759887, Tazobactam, YTR-830H, tazobactam, TAZOBACTAM

Parent form; salt/anhydrous children: CHEMBL1439

Patent coverage: 3,932 distinct patent families (13,227 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 13 (assay-derived). Sample: Beta-lactamase, Beta-lactamase, Beta-lactamase TEM, Beta-lactamase TEM, Beta-lactamase, Beta-lactamase, Beta-lactamase OXA-1, Beta-lactamase, Beta-lactamase SHV-1, Beta-lactamase.

Bioactivity

ChEMBL activities: 38 potent at pChembl ≥ 5 of 47 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
P62593	7.77	IC50	17	nM	CHEMBL_ACT_1917353
P62593	7.76	IC50	17.2	nM	CHEMBL_ACT_17702878
P62593	7.6	IC50	25	nM	CHEMBL_ACT_971161
P62593	7.22	IC50	60	nM	CHEMBL_ACT_1106017
P62593	7.05	IC50	90	nM	CHEMBL_ACT_2125195
P62593	7	IC50	100	nM	CHEMBL_ACT_1740667
P05364	7	IC50	100	nM	CHEMBL_ACT_284133
P62593	7	IC50	100	nM	CHEMBL_ACT_59899
P0AD64	6.96	IC50	110	nM	CHEMBL_ACT_3475754
P62593	6.89	IC50	130	nM	CHEMBL_ACT_2635602
P05364	6.82	IC50	150	nM	CHEMBL_ACT_835196
P62593	6.72	Ki	190	nM	CHEMBL_ACT_19131302
P94958	6.72	IC50	190	nM	CHEMBL_ACT_835183
P0AD63	6.65	IC50	222	nM	CHEMBL_ACT_17702877
P0AD63	6.65	IC50	222	nM	CHEMBL_ACT_1917368
P05364	6.62	IC50	240	nM	CHEMBL_ACT_835199
P00811	6.6	IC50	250	nM	CHEMBL_ACT_155840
Q9F663	6.43	IC50	374	nM	CHEMBL_ACT_2304524
Q9F663	6.43	IC50	370	nM	CHEMBL_ACT_3387682
P05364	6.38	IC50	420	nM	CHEMBL_ACT_835194
P00807	6.3	IC50	500	nM	CHEMBL_ACT_835193
P00808	6.29	IC50	510	nM	CHEMBL_ACT_835192
P05364	6.25	IC50	560	nM	CHEMBL_ACT_835195
P05364	6.25	IC50	560	nM	CHEMBL_ACT_835198
P24735	6.09	IC50	820	nM	CHEMBL_ACT_835188
P05364	6.08	IC50	830	nM	CHEMBL_ACT_835200
P05193	6.03	IC50	930	nM	CHEMBL_ACT_835184
P05364	6.03	IC50	930	nM	CHEMBL_ACT_835197
P05364	6.03	IC50	943	nM	CHEMBL_ACT_971160
P05364	5.89	IC50	1300	nM	CHEMBL_ACT_5298784

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

24 indications (1 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
bacterial infectious disease	4	MONDO:0005113	EFO:0000771
Pseudomonas infection	3	MONDO:0005141	EFO:0001076
abscess	3	MONDO:0005227	EFO:0003030
pneumonia	3	MONDO:0005249	EFO:0003106
toxic shock syndrome	3	MONDO:0001881	EFO:0006834
bacterial pneumonia	3	MONDO:0004652	EFO:1001272
acute cholecystitis	3	MONDO:0043994	EFO:1001289
urinary tract infection	3	MONDO:0100338	EFO:0003103
pyelonephritis	3	MONDO:0006939	EFO:1001141
hematopoietic and lymphoid system neoplasm	3	MONDO:0002334	MONDO:0044881
influenza	3	MONDO:0005812	EFO:0007328
severe acute respiratory syndrome	3	MONDO:0005091	MONDO:0100096
lung disorder	3	MONDO:0005275	EFO:0003818
infectious disease	2	MONDO:0005550	EFO:0005741
graft versus host disease	2	MONDO:0013730	MONDO:0013730
appendicitis	2	MONDO:0005649	EFO:0007149
otitis media	1	MONDO:0005441	EFO:0004992
kidney disorder	1	MONDO:0005240	EFO:0003086
osteomyelitis	0	MONDO:0005246	EFO:0003102

5 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.

Clinical trials

Total trials: 69.

Phase distribution

Phase	Trials
Not specified	22
PHASE4	19
PHASE3	13
PHASE2	7
PHASE1	7
PHASE1/PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT03671967	PHASE4	RECRUITING	PipEracillin Tazobactam Versus mERoPENem for Treatment of Bloodstream Infections Caused by Cephalosporin-resistant Enterobacteriaceae (PETERPEN)
NCT06184659	PHASE4	RECRUITING	Empirical Meropenem Versus Piperacillin/Tazobactam for Adult Patients With Sepsis
NCT07484633	PHASE4	NOT_YET_RECRUITING	A Study to Compare the Efficacy and Safety of Extended and Intermittent Infusion of Beta-lactams in Critically Ill Paediatric Patients
NCT07556107	PHASE4	NOT_YET_RECRUITING	The Vancomycin Piperacillin/Tazobactam (VPT) Patient Safety Trial (VPS)
NCT00044746	PHASE4	COMPLETED	Study Evaluating the Safety and Efficacy of Piperacillin/Tazobactam and Ampicillin/Sulbactam in Patients With Diabetic Foot Infections
NCT00044928	PHASE4	COMPLETED	Study Evaluating Zosyn in Hospitalized Patients With Intra-abdominal Infection
NCT00703144	PHASE4	COMPLETED	Pharmacokinetics of Piperacillin/Tazobactam in Patients Treated by Continuous Renal Replacement Therapy
NCT00816790	PHASE4	TERMINATED	Standard Vs Adjusted Dosing of Piperacillin/Tazobactam in Acute Renal Failure and Septic Shock
NCT02421120	PHASE4	COMPLETED	Population Pharmacokinetics and Safety of Intravenous Ceftolozane/Tazobactam in Adult Cystic Fibrosis Patients
NCT02463747	PHASE4	UNKNOWN	Short vs Prolonged Antibiotic Treatment for Hospitalized Hemato-oncology Patients With Febrile Neutropenia
NCT02991937	PHASE4	COMPLETED	Comparison of Medical and Surgical Treatment of Uncomplicated Acute Appendicitis in Children
NCT03002506	PHASE4	TERMINATED	Pharmacokinetics of Ceftolozane/Tazobactam in Patients With Burns
NCT03262142	PHASE4	TERMINATED	Targeted AntiBiotics for Chronic Pulmonary Diseases
NCT03560232	PHASE4	TERMINATED	Noninferiority Comparison of Prophylactic Open Fracture Antimicrobial Regimens
NCT03891433	PHASE4	SUSPENDED	Piperacillin/Tazobactam Versus Carbapenems in Non-bacteremic UTI Due to -ESBL-producing Enterobacteriaceae
NCT04948463	PHASE4	COMPLETED	Early Versus Late Stopping of Antibiotics in Children With Cancer and High-risk Febrile Neutropenia
NCT05102162	PHASE4	TERMINATED	BL Infusion Trial:Beta-lactam Continuous Versus Intermittent Infusion and Associated Bacterial Resistance and Therapy Outcomes in Critically Ill Patients With Severe Pneumonia
NCT05981079	PHASE4	UNKNOWN	Model-based Dose Versus Empirical Dose of Piperacillin/Tazobactam in Preterm Neonates With Late-onset Sepsis.
NCT06035055	PHASE4	UNKNOWN	Ceftolozane/Tazobactam Continuous Infusion for Infective Exacerbations of Cystic Fibrosis and Bronchiectasis
NCT00229112	PHASE3	COMPLETED	Comparative Study of Ertapenem Versus Another Antibiotic in the Treatment of Diabetic Foot Infections in Adults (0826-034)
NCT00253955	PHASE3	COMPLETED	Study to Demonstrate the Clinical Efficacy of Levofloxacin in the Treatment of Pneumonia
NCT00629135	PHASE3	COMPLETED	Moxifloxacin Plus Metronidazole Versus Piperacillin/Tazobactam for the Treatment of Patients With Intra-abdominal Abscesses
NCT01853982	PHASE3	TERMINATED	Study of Intravenous Ceftolozane/Tazobactam Compared to Piperacillin/Tazobactam in Ventilator-Associated Pneumonia
NCT02070757	PHASE3	COMPLETED	Safety and Efficacy Study of Ceftolozane/Tazobactam to Treat Ventilated Nosocomial Pneumonia (MK-7625A-008)
NCT02473263	PHASE3	COMPLETED	Samu Save Sepsis: Early Goal Directed Therapy in Pre Hospital Care of Patients With Severe Sepsis and/or Septic Shock
NCT02493764	PHASE3	COMPLETED	Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014)
NCT02728089	PHASE3	COMPLETED	Study of Ceftolozane/Tazobactam (MK-7625A) in Japanese Participants With Uncomplicated Pyelonephritis and Complicated Urinary Tract Infection (MK-7625A-014)
NCT02739997	PHASE3	COMPLETED	Study of Ceftolozane/Tazobactam (MK-7625A) in Combination With Metronidazole in Japanese Participants With Complicated Intra-abdominal Infection (MK-7625A-013)
NCT03006679	PHASE3	WITHDRAWN	A Study of Meropenem-Vaborbactam Versus Piperacillin/Tazobactam in Participants With Hospital-Acquired and Ventilator-Associated Bacterial Pneumonia
NCT03687255	PHASE3	COMPLETED	Safety and Efficacy Study of Cefepime-AAI101 in the Treatment of Complicated Urinary Tract Infections
NCT03830333	PHASE3	COMPLETED	Ceftolozane/Tazobactam (MK-7625A) Plus Metronidazole Versus Meropenem for Participants With Complicated Intra-abdominal Infection (MK-7625A-015)
NCT04042077	PHASE3	TERMINATED	Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections
NCT00438269	PHASE2	COMPLETED	Pilot Study of the Utility of Empiric Antibiotic Therapy for Suspected ICU-Acquired Infection
NCT02732327	PHASE2	TERMINATED	Comparative Study of Ceftazidime-Avibactam Versus Standard of Care as Therapy in Febrile Neutropenic Adults With Cancer
NCT03217136	PHASE2	COMPLETED	MK-7625A Plus Metronidazole Versus Meropenem in Pediatric Participants With Complicated Intra-Abdominal Infection (cIAI) (MK-7625A-035)
NCT03230838	PHASE2	COMPLETED	MK-7625A Versus Meropenem in Pediatric Participants With Complicated Urinary Tract Infection (cUTI) (MK-7625A-034)
NCT03309657	PHASE1/PHASE2	COMPLETED	Pharmacokinetics of Ceftolozane/Tazobactam in Plasma and Cerebrospinal Fluid
NCT03485950	PHASE2	COMPLETED	Comparative Study To Determine The Efficacy, Safety, And Tolerability Of Ceftolozane-Tazobactam
NCT05753735	PHASE2	TERMINATED	eXtended Antibiotic Prophylaxis for Intermediate- and High-risk Glands After Pancreatoduodenectomy to Reduce CR-POPF
NCT05943223	PHASE2	UNKNOWN	Piperacillin/Tazobactam Versus ceftriAxone and Metronidazole for Children With Perforated Appendicitis (ALPACA)

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).